Neurogene Inc. (NASDAQ: NGNE) had its price target lowered by analysts at HC Wainwright from $55.00 to $51.00. They now have a "buy" rating on the stock.
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting [Yahoo! Finance]
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting
Neurogene Inc. (NASDAQ: NGNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.